ZDA
RYTM icon

Zweig-DiMenna Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History

Zweig-DiMenna Associates’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.67M Buy
+42,100
New +$3.81M 0.42% 54
2026
Q1 		– Sell
-81,600
Closed -$8.73M – 93
2025
Q4 		$8.73M Buy
+81,600
New +$8.66M 0.54% 61

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Zweig-DiMenna Associates's RYTM Position: Q2 2026 in Review

Zweig-DiMenna Associates opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 42,100 shares worth $4.67M. The stake represents 0.42% of the portfolio and ranks #54 among its holdings. This is a return to the name: Zweig-DiMenna Associates previously reported a position in RYTM as recently as Q4 2025.

Zweig-DiMenna Associates first reported a position in RYTM in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.73M in Q4 2025. 305 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Zweig-DiMenna Associates held 42,100 shares of Rhythm Pharmaceuticals worth $4.67M as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Zweig-DiMenna Associates position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.42% of Zweig-DiMenna Associates's portfolio in Q2 2026, its #54 holding.
  • Zweig-DiMenna Associates first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Zweig-DiMenna Associates's Rhythm Pharmaceuticals position peaked at $8.73M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2026, filed 13 Aug 2026.